← Back

Nanjing Xinjiekou Department Store Co Ltd

Nanjing Xinjiekou Department Store Co., Ltd. is involved in the retail department store business in China. It is also involved in modern commerce, health and elderly care, and biomedicine, as well as property management. The company was founded in 1952 and is based in Nanjing, China.

Price · split & dividend adjusted
News & notes moving 600682.CG
Aging Population

Nanjing Xinjiekou Department Store posts first-half revenue of 2.89 billion yuan as dual-engine strategy gains traction

Nanjing Xinjiekou Department Store disclosed its 2026 semi-annual report on the evening of August 26, reporting first-half operating revenue of 2.89 billion yuan and total profit of 163 million yuan. The company adhered to its dual-engine strategy of "big health plus new consumption," with progress across its modern commerce, health and elderly care, and biomedical segments. In modern commerce, the company advanced store renovations, introduced first stores and benchmark brands, and created younger-oriented consumption scenarios. In health and elderly care, Ankangtong won 82 projects, while overseas subsidiary Natali completed the acquisition and integration of several UK elderly care companies. In biomedicine, Qilu Stem Cell completed filings for two new technologies, and Dendreon China's Provenge is in Phase III clinical follow-up. The company said it will continue to seize opportunities in the silver economy and the cell and gene therapy industry to promote high-quality development.
证券时报·1dRead more ▾
600682.CG2

Nanjing Xinbai's first-half net profit falls 78.43% year on year

Nanjing Xinbai disclosed its semi-annual report on August 26. In the first half of 2026, it achieved total operating revenue of 2.89 billion yuan, down 10.02% year on year. Net profit attributable to shareholders of the listed company was 35.91 million yuan, down 78.43% year on year. Basic earnings per share were 0.03 yuan.
证券时报·1dRead more ▾
600682.CG2

Nanjing Xinbai Expects First-Half 2026 Net Profit to Drop Over 77% Year-on-Year

Nanjing Xinbai has disclosed its earnings forecast, expecting attributable net profit for the first half of 2026 to be between 35.12 million yuan and 38.05 million yuan, a year-on-year decline of 77.15% to 78.9%. Deducted non-recurring net profit is expected to be between 6.62 million yuan and 9.55 million yuan, a year-on-year drop of 92.94% to 95.1%. The company stated that the decline in performance is mainly due to lower sales of the product PROVENGE by Dendreon Pharmaceuticals LLC, which is controlled by its wholly-owned subsidiary Shiding Biotechnology Hong Kong Company Limited, reducing Shiding Hong Kong's net profit by approximately 142 million yuan.
中国证券报·43dRead more ▾